lexaria bioscience corp. lxx:cse | lxrp:us drug delivery ... · natural fat soluble vitamins (a, d,...
TRANSCRIPT
1
Lexaria Bioscience Corp. LXX:CSE | LXRP:US
Drug Delivery Platform Innovator
Investor PresentationApril 2019
LexariaBioscience.com
2Investor Presentation
DisclaimerThis presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, andSection 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements.The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows,financing plans, business strategy, products and services, evaluation of medical marijuana projects, alternative health projects or products,and cannabidiol-fortified products or services for participation and/or financing, competitive positions, growth opportunities, plans andobjectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan,""estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions that are forward-looking statements. Suchforward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number ofrisks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statementsincluding, without limitation, foreign exchange and other financial markets; changes of the interest rates on borrowings; whether or not theCompany will be successful in executing its business plan in whole or in part; hedging activities; changes in commodity prices; changes inthe marketing or capital project expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitivedevelopments in areas in which Lexaria Corp. operates. These and other risks and uncertainties are more fully described in our periodicreports and other disclosure documents filed by Lexaria Corp. from time to time with regulatory authorities available on SEDAR atwww.sedar.com and on EDGAR at www.sec.gov, and the reader is encouraged to review these documents. Planned dates stated herein areestimates only, based on best information available. Dates are not assured and are subject to revision without notice. The Companyassumes no obligation, except as required by law, to update any forward-looking statement, whether as a result of new information, futureevents or otherwise. This presentation is not an offer to sell or a solicitation of an offer to buy securities of Lexaria Bioscience Corp. It is ashort summary of certain information for introductory purposes only and is not to be relied upon for investment purposes.
No statement within has been evaluated by the Food and Drug Administration, and no product or service is intended to diagnose, treat,cure or prevent any disease.
2
3Investor Presentation
Simple and cost effective
Increases bioavailability
Improves speed of onset
Masks unwanted taste
Drug Delivery Platform Innovator
Eliminates the need for sugar-filled edibles.
Equates that of less healthy
administration methods like
inhalation
Effects are felt within 10-20 min (vs. 60-120 min).
Easy to implement
DehydraTECHTM - Patented technology, Changing the way Active Pharmaceutical Ingredients (“APIs”) enter the body orally
Eliminates the need for sugar-filled edibles.
4Investor Presentation
Method of use &Composition of matter claims• Cannabinoids (CBD, THC)• Nicotine (and its analogs)• NSAIDs• Fat soluble vitamins
Multiple dosage forms - foods, liquid emulsions, tablets, capsules
50+ Patent Applications
10Patent Families
10Patents Granted
6 USA4 Australia
DehydraTECH™ Patent Portfolio
5Investor Presentation
NicotineNSAIDsVitaminsCannabis
Commercial Applications
5
• Ingestible product formats of all types,•Enhanced palatability, speed of effectiveness and potency,•Viable and healthier alternative to smoking/vaping.
•Existing and new ingestible product formats,•Enhanced absorption performance for synthetics as well as natural fat soluble vitamins (A, D, K & E).
•Alternate means to formulate NSAIDs,•Higher bioavailability,•Lower input requirements,•Less burden on liver and kidneys (lower toxicity).
•World’s first ingestible nicotine products,•Alternative to smoking/vaping, gums and patches,•High bioavailability without first pass liver metabolism.
Estimated Global Market Sizes
Sources: ArcView Research & EuroMonitor
$13B $31B $60B $990B
6Investor Presentation
6
Cannabinoids | THC | CBD
Oral Delivery
7Investor Presentation
Cannabinoids: Entering the Blood Stream
7
3 prominent ways cannabinoids enter the blood stream:
Inhalation High bioavailability (est. 30%)Harmful to Lungs
Sub-lingual (under tongue) Medium bioavailability (est. 16%)Foul taste
Oral – Gastrointestinal TractLow bioavailability (est. 3-5%)Sugar filled, to mask taste
DehydraTECHTM
transforms the way cannabinoids enter the
bloodstream through the Gastrointestinal Tract:
Fast ActingImproved Taste
Increased Bioavailability
8Investor Presentation
Consumer Shift Away From Flower
Market share for flower is eroding – even though the market is growing and prices are dropping.
66 62 59 54 44
34 38 41 46 56
2014 2015 2016 2017 Q1 2018
Colorado
54 44
46 56
Q1 '17 Q1 '18
Oregon
43 40
57 60
Jan '18 April '18
California
$372M
$4.94/g
Q1 2014 (Colorado) Q1 2018
Non-flower
Market share %
Flower
Source: colorado.gov bdsanalytics.com
$7.12/g
$150M
Apr May Jun Jul Aug Sept
Cannabis Oil 3734 4406 4124 4310 4391 4455
Dried Cannabis 2354 2310 2103 2151 2069 1755
37344406 4124 4310 4391 4455
Canada:Cannabis sold to clients during 2018 (kg)
In Canada’s tightly regulated market (with limited product
formats), consumers are moving away from smoking.
Source: canada.ca
9Investor Presentation
Cannabis Consumption Trends
Trend to limit dosage in
edibles
Trend away from smoking
Trend toward beverages &
edibles
DehydraTECH™Improves
cannabinoid absorption
DehydraTECH™Improves alternate
delivery methods
DehydraTECH™spans foods, beverages, nutritional supplements and more
10Investor Presentation
Cannabinoid Absorption - Clinically Proven
Double-blind90 mg dose
317% more CBD delivered ≤ 30 min.
Higher CBD delivery throughout entire study
Lower blood pressure, (95% CI; p=0.027)
Higher blood flow to the brain0
10
20
30
40
50
60
0 100 200 300 400
Pla
sma
con
cen
trat
ion
(n
g/m
L)
Time (min)
Plasma Concentration Comparison
TurboCBD™DehydraTECHTM
Control
European human clinical study:
A single 90mg dose of TurboCBDTM provided evidence of lower blood pressure; higher blood flow to the brain; faster delivery onset of CBD into the bloodstream; and larger quantities of CBD within the blood when compared to a single 90mg dose of generic CBD.
317% more CBD delivered≤ 30 min.
11Investor Presentation
Out-license to third-party partners High margin royalty modelExample licensees:Demonstration products
TurboCBD™ capsules ViPova™ teas
Distribution partnerships
Innovation & ResearchNew product development
Patent applicationsClinical trials
Business Model: Royalties & Sales
1906 New Highs (Colorado)
Hill Street Beverages(TSX.V:BEER )
Cannfections Group(Canada)
12Investor Presentation
12
Lexaria Nicotine
Oral Nicotine Delivery Forms
LexariaNicotineCo.com
13Investor Presentation
Nicotine: a smoke-free future?
NoNicotine edibles
due to nicotine’s inability to securely pass through the GI
tract without irritation.
Phillip Morris
pledges $1B to anti-smoking
1.1 billion smokers globally
7 million deaths/year globally
1 billion deaths expected this century
lowering nicotine in
cigarettes to non-
addictive levels
FDA Comprehensive regulatory plan to shift trajectory of tobacco-related disease,
death
Smoking is the world's leading
cause of preventable
death
“Ultimately, we want to
be in a position to stop selling cigarettes
entirely.”-- André Calantzopoulos,
Phillip Morris CEO, May 30, 2018.
World Health Organization (www.who.int)Foundation for a Smoke-Free World, Inc. (www.smokefreeworld.org)
British American Tobacco
to rapidly expand “next-gen products”
14Investor Presentation
Altria Group Inc.Funding Partner, DehydraTECH Licensee
Leading nicotine industry
participant
Patentedoral-based
delivery technique
Altria GroupLeader in authorized,
non-combustible, reduced-risk products.
Lexaria NicotineLeader in unique alternate gastro-intestinal delivery methods for orally-administered products.
Product development
for orally-administered
nicotine formats
Lexaria Nicotine• Majority-owned subsidiary of
Lexaria Bioscience,• Holds DehydraTECH license
rights for nicotine related use.
Altria Group• DehydraTECH licensee for oral &
non-combustible nicotine formats,• Ownership investment in Lexaria
Nicotine to fund further research.
Definitive Agreement signed January 15, 2019
15Investor Presentation
Completing the puzzle for Oral Nicotine Forms
Market needFDA – comprehensive plan to reduce smoking
Collaborative ResearchAltria Group & Lexaria Nicotine
to conduct animal & human studies
Altria Group - Strategic Funding Partner
Initial Funding: US$1 millionMilestone based: up to US$12 million
DehydraTECHTM
• Altria Group has licensed DehydraTECH to commercialize oral, non-combustible nicotine products,
• Exclusive license in the United States,• Non-exclusive globally,• Royalty-based payment structure.
16Investor Presentation
DehydraTECHTM: In vivo research
Study of 12 lab rats over 6 hour period showed560% more nicotine
delivered into brain tissueApril 17, 2018
Study of 40 lab rats, with focus on initial 15 minute
period after dosing.August 7, 2018
70% more
nicotine delivered overall
within first 15
min of study
(p=0.0004)
90%more
nicotine delivered at 10
minute mark
(p=0.044)
94%more
nicotine delivered over the
60 min study period(p=0.0086)
179% gain in the quantity of peak nicotine delivery
to the bloodstream relative to controls
Speed of onset is of particular importance when considering non-inhalation nicotine delivery formatsDehydraTECHTM delivered:
17Investor Presentation
Control DehydraTECH™ % Improvement(10 mg/Kg) (10 mg/Kg)
Nicotine: Blood-Brain-Barrier ResultsSignificant nicotine absorption increase across the Blood-Brain Barrier into brain tissue:
40 lab rat testAug 7, 2018
Testing at 1, 4, 8, 24 hrs.
12 lab rat test Apr 17, 2018
Maximum Brain Concentration (Cmax; ng/ g)
427 ± 66.5 1,260 ± 200 295%
Maximum Brain Concentration (Cmax; ng /g)
51.8 ± 30.4 290 ± 197 560%
Time to Cmax 4 hours 1 hour 400%
04Total Quantity in Brain Tissue (AUC; hr·ng/g)
5,881 ± 538 12,999 ± 1252 221%
18Investor Presentation
Key Executives
Serial entrepreneur involved in several private and public companies since the late 1980’s,
Extensive experience in the capital markets, corporate governance, M&A and finance.
Experienced executive in the pharmaceutical and bioscience sectors,Specialist in development of drug delivery technologies,Former President and COO of Helix BioPharma Corp. (TSX: HBP). Named inventor on multiple issued and pending patents. M.Sc. in pharmacology and B.Sc. in toxicology from the University of Toronto.
U.S. licensed patent attorney,Doctorate in Neuroscience (with concentrations in Pharmacology and Physiology), Over 15 years of experience providing patent services to clients that have ranged from small start-ups to some of the world’s largest pharmaceutical and biotechnology companies.
Co-Director for the Centre for Heart, Lung and Vascular Health, Canada,
Research Chair in Cerebrovascular Physiology and Professor, School of Health and Exercise Sciences,
Faculty of Health and Social Development at the University of British Columbia.
Chris Bunka
Chairman & CEO
John Docherty, M.Sc.
Director & President
Dr. Edward Ergenzinger
Chief Legal, SVP Innovation
Dr. Philip AinslieAdvisor
19Investor Presentation
Corporate Information
19
One year stock chart – OTCQX:LXRP
Chris Bunka John Docherty Alex Blanchard
CEO President Manager Corp. Comm & IR
250 765 6424 905 439 5423 778 796-1897
[email protected] [email protected] [email protected]
Trading symbol: LXX:CSE, LXRP:OTCQX
Shares o/s: 77 m
Fully diluted: 86 m
Recent price: C$1.55 / US$1.15
Insider ownership: 15m (20%)
Fiscal year-end: August 31
Cash on hand (Nov ‘18) US$ 2.6M
Recent financing (Oct ‘18) US$1.5M (@ US$1.60/unit)
Lexaria Bioscience Corp. 100-740 McCurdy Road, Kelowna, BC, V1X 2P7